Gold prices bounce off 3-week lows; demand likely longer term
Robert Thomas Freeman, the Chief Financial Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently executed significant stock transactions involving the company’s common stock. According to a recent SEC filing, Freeman sold a total of 468,295 shares across two separate transactions. The sales come as ALHC trades near its 52-week high of $16.25, with the stock delivering an impressive 183% return over the past year. InvestingPro data shows the company maintains a GOOD financial health score despite current profitability challenges.
On March 4, 2025, Freeman sold 250,000 shares at a weighted-average price of $15.5831 per share, generating approximately $3.9 million. The sale was conducted under a pre-established trading plan adopted on November 25, 2024.
Additionally, on March 6, 2025, Freeman sold another 218,295 shares at a weighted-average price of $15.53 per share, amounting to roughly $3.4 million. This sale was executed to cover tax withholding obligations related to the vesting of performance share units (PSUs).
Following these transactions, Freeman holds 1,417,554 shares directly. An additional 92,929 shares are held indirectly through FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, of which Freeman is an indirect beneficiary.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing expectations with an EPS of -0.16 against a forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million compared to the expected $674.97 million. For the full year, Alignment Healthcare’s revenue amounted to $2.7 billion, marking a 48% increase year-over-year. Piper Sandler recently raised its price target for Alignment Healthcare to $21.00, maintaining an Overweight rating, citing the company’s scalable processes and high Star Ratings as key strengths. Similarly, Raymond (NSE:RYMD) James increased its price target to $19.00, maintaining a Strong Buy rating, following the company’s robust performance, including a 59% membership growth and lower-than-expected medical loss ratio. Looking ahead, Alignment Healthcare has provided 2025 guidance, projecting revenue between $3.72 billion and $3.78 billion, with an expected membership growth to between 227,000 and 233,000 members. The company also anticipates an adjusted EBITDA range of $35 million to $60 million, reflecting continued confidence in its operational strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.